MK-1308-001
16 Dec 2020
MK-1308-001
NCT03179436
A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab for subjects with advanced solid tumours
Merck
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2017-07-02 |
Anticipated End Date | 2022-10-24 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Brian Stein |
Recruitment Status | Recruiting |